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Abstract
Background: The five-tiered Cambridge Prognostic Group (CPG) classification is a better predictor of prostate
cancer-specific mortality than the traditional three-tiered classification (low, intermediate, and high risk). We
investigated radical treatment rates according to CPG in men diagnosed with non-metastatic prostate cancer in
England between 2014 and 2017.
Methods: Patients diagnosed with non-metastatic prostate cancer were identified from the National Prostate
Cancer Audit database. Men were risk stratified according to the CPG classification. Risk ratios (RR) were estimated
for undergoing radical treatment according to CPG and for receiving radiotherapy for those treated radically.
Funnel plots were used to display variation in radical treatment rates across hospitals.
Results: A total of 61,999 men were included with 10,963 (17.7%) in CPG1 (lowest risk group), 13,588 (21.9%) in
CPG2, 9452 (15.2%) in CPG3, 12,831 (20.7%) in CPG4, and 15,165 (24.5%) in CPG5 (highest risk group). The
proportion of men receiving radical treatment increased from 11.3% in CPG1 to 78.8% in CGP4, and 73.3% in CPG5.
Men in CPG3 were more likely to receive radical treatment than men in CPG2 (66.3% versus 48.4%; adjusted RR
1.44; 95% CI 1.36–1.53; P < 0.001). Radically treated men in CPG3 were also more likely to receive radiotherapy than
men in CPG2 (59.2% versus 43.9%; adjusted RR, 1.18; 95% CI 1.10–1.26). Although radical treatment rates were
similar in CPG4 and CPG5 (78.8% versus 73.3%; adjusted RR 1.01; 95% CI 0.98–1.04), more men in CPG5 had
radiotherapy than men in CPG4 (79.9% versus 59.1%, adjusted RR 1.26; 95% CI 1.12–1.40).
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Conclusions: The CPG classification distributes men in five risk groups that are about equal in size. It reveals
differences in treatment practices in men with intermediate-risk disease (CPG2 and CPG3) and in men with high-risk
disease (CPG4 and CPGP5) that are not visible when using the traditional three-tiered risk classification.
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Introduction
The Cambridge Prognostic Group (CPG) classification
provides a five-tiered prostate cancer risk classification
for non-metastatic prostate cancer. It has been shown to
be a better predictor of prostate cancer deaths than trad-
itional three-tiered classifications including those recom-
mended by the UK National Institute for Health and
Care Excellence (NICE) and the European Association
of Urology (EAU) [1, 2].
The CPG classification was developed in an unscreened
primary diagnostic cohort, encompassing all treatment
types, making it truly a representative of a contemporary,
real-world population [3]. A follow-up validation study
confirmed that the five-tiered classification better pre-
dicted prostate cancer death across different ages and
treatment groups than three-tiered classifications [4].
The core differences between the CPG system and the
traditional three-tiered systems are the subdivision of
intermediate-risk disease into CPG2 with favourable fea-
tures (Gleason score 3 + 4 or PSA 10–20) and CPG3
with unfavourable features (Gleason score 3 + 4 and PSA
10–20, or Gleason score 4 + 3) as well as the subdivision
of high risk into CPG4 (one high-risk feature of Gleason
score 8, PSA > 20 or T3) and CPG5 (more than one
high-risk feature of Gleason score 9–10 or T4) (Table 1)
[3, 5]. With this finer degree of granularity, the CPG
classification is the first reported classification system of
prostate cancer risk that incorporates recommendations
of the International Society of Urological Pathology on
the grading of prostate cancer [6]. The American Uro-
logical Association [7] and the National Comprehensive
Cancer Network [8] have both adopted subgroups for
intermediate- and high-risk disease, but recent work has
now shown that the CPG classification outperforms even
these other approaches in head-to-head comparisons [2].
The National Prostate Cancer Audit (NPCA) has
been collecting prospective data on every man newly
diagnosed with prostate cancer in England and Wales
since April 2014. So far, the Audit has only used the
three-tiered classification system [9]. The aim of this
study was to assess the disease presentation and treat-
ment selection for men diagnosed with non-
metastatic prostate cancer in England according to
the CPG risk classification system.
Table 1 Patient characteristics of men diagnosed with non-metastatic prostate cancer receiving radical treatment according to the
Cambridge Prognostic Group (CPG) classification
CPG Criteria 10-year risk of dying from prostate cancer
without treatment* (%)
10-year risk of dying from prostate
cancer with treatment* (%)
1 Gleason score 6 (grade group 1)
AND PSA < 10 ng/ml
AND stages T1–T2
4.2 1.2
2 Gleason score 3 + 4 = 7 (grade group 2)
OR PSA 10–20 ng/ml AND stages T1–T2
4.7 2.3
3 Gleason score 3 + 4 = 7 (grade group 2)
AND PSA 10–20 ng/ml
AND stages T1–T2
OR
Gleason score 4 + 3 = 7 (grade group 3)
AND stages T1–T2
15.1 3.2
4 One of the following:
Gleason score 8 (grade group 4)
OR PSA > 20 ng/ml
OR stage T3
N/A** 5.8
5 Any combination of Gleason score 8 (grade group 4),
PSA > 20 ng/ml or stage T3
OR Gleason score 9–10 (grade group 5)
OR stage T4
N/A** 13.7
*Mortality is taken from Gnanapragasam et al. [3]
*No reliable data is available for untreated men with CPG4 or CPG5
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Methods
Patient population
Our study used the NPCA database to identify 118,526
men diagnosed with non-metastatic prostate cancer be-
tween April 1, 2014, and March 31, 2017, at an English
National Health Service (NHS) hospital using the
International Classification of Diseases, 10th Edition
(ICD-10) code ‘C61’ [10]. The NPCA database includes
staging data from the English Cancer Registry [11], ad-
ministrative hospital data from the Hospital Episode
Statistics database [12], and treatment data from the
Radiotherapy Dataset (RTDS) [13]. English Cancer
Registry data includes all men newly diagnosed with
prostate cancer [14]. We excluded 20,538 men with
stage M1 or PSA ≥ 100 (17.3%), 4447 men with stage N1
(3.8%), and 31,642 men because of missing staging
(26.7%). As a result, 61,999 patients were included in
our study.
We classified the included patients according to the
CPG classification using Gleason score, PSA level, and
TNM as outlined in Table 1. For comparison, we also
classified the men according to the three-tiered NPCA
risk classification [9], which is based on the NICE rec-
ommendation (low, intermediate, and high risk) with
modifications to accommodate the unavailability of sta-
ging data required to subdivide stage T2 into T2a, T2b,
or T2c [1].
Patient characteristics including age, ethnicity (white
and non-white), and socioeconomic deprivation status
were identified using Hospital Episode Statistics (HES)
data. Socioeconomic deprivation status was determined
for patients from the English 2015 Index of Multiple
Deprivation (IMD) based on their area of residence and
divided according to quintiles of the national distribu-
tion [15]. We used ethnicity available from the English
Cancer Registry to supplement any missing values in
HES. The Royal College of Surgeons (RCS) Charlson
score was used to identify any comorbid conditions ac-
cording to diagnosis codes in the HES records within
1 year of diagnosis [16].
Study outcome
We identified the treatments that men received using
HES and RTDS data. The OPCS Classification of Inter-
ventions and Procedures (OPCS-4) code ‘M61’ in HES
was used to identify men who underwent a primary rad-
ical prostatectomy and the date of the operation [17].
The data item ‘treatment modality’ in the RTDS was
used to select men who underwent primary radical
radiotherapy and the start date of this treatment. Pri-
mary radical treatment was defined as either radical
radiotherapy or a radical prostatectomy within 1 year of
diagnosis. For those undergoing more than one radical
treatment, the primary treatment was selected based on
the earliest treatment date, i.e. a patient who received
surgery followed by radiotherapy was analysed in the
surgery group.
Statistical analysis
Multivariable multilevel Poisson regression with robust
standard errors was used to estimate the risk ratio (RR)
comparing the proportion of men who had radical treat-
ment, compared to the proportion of men who did not,
according to CPG and adjusted for age, Charlson score,
socioeconomic deprivation status, and ethnicity [18]. A
random intercept was modelled for each hospital to ad-
just for clustering within hospitals. A further Poisson re-
gression model was used for the men who received
radical treatment to estimate adjusted risk ratios com-
paring the proportion of men having had radiotherapy
as their primary treatment, compared to the proportion
of men having surgery, according to CPG. Missing data
for ethnicity (3.1%) were imputed with multiple imput-
ation using chained equations to create ten data sets.
Rubin’s rules were then used to combine the risk ratios
across these ten data sets. Wald tests were used to calcu-
late P values with significance set at P < 0.05.
Between-hospital variation in adjusted radical treat-
ment rates was explored visually using funnel plots to
establish whether this variation in the proportion of pa-
tients receiving radical treatment was greater than ex-
pected by chance alone for each CPG [19]. Control
limits corresponding to two standard deviations from
the national average population (95%) were set for each
CPG funnel plot. The proportion of hospitals outside of
these limits was used to quantify the between-hospital




Of the 61,999 men with non-metastatic prostate cancer
included in the study, 10,963 were grouped in CPG1
(17.7%) as the lowest risk group, 13,588 in CPG2
(21.9%), 9452 in CPG3 (15.2%), 12,831 in CPG4 (20.7%),
and 15,165 in CPG5 (24.5%) as the highest risk group
(Fig. 1). CPG1 included more men than the 5588 men in
the low-risk group of the traditional three-tiered classifi-
cation given that T2 cases were also included. CPG2 and
CPG3 included all remaining men in the intermediate-
risk group, and CPG4 and GP5 included all men in the
high-risk group.
Apart from the patients’ age, patient characteristics
were similar across CPGs (comorbidities, deprivation
status, and ethnicity). The proportion of older men
(≥ 70 years) increased with CPG (CPG1, 30.7; CPG2,
37.2; CPG3, 52.3; CPG4, 47.8; CPG5, 60.4) (Table 2).
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Radical treatment by prognostic group
The proportion of men who received radical treatment
increased in men with higher risk according to their
CPG (P < 0.001) and older age (P < 0.001), and decreased
in men with more comorbidities (Table 3). As expected,
men in CPG1 were least likely to receive radical treat-
ment (11.3%). Of the 5588 men in CPG1 with T1
disease, who have low-risk disease according to the
three-tiered classification, 5.1% received radical treat-
ment compared to 17.7% of the 5375 men in CPG1 with
T2 disease, who have intermediate-risk disease according
to the three-tiered system (adjusted RR 3.53; 95% CI
2.61–4.78; P < 0.001).
Men in CPG3 were more likely to receive radical treat-
ment than those in CPG2 (66.3% versus 48.4%; adjusted
RR 1.44; 95% CI 1.36–1.53; P < 0.001). The overall pro-
portion of men receiving radical treatment was slightly
higher in men in CPG4 (78.8%) than in CPG5 (73.3%),
but this difference was not statistically significant (ad-
justed RR 1.01; 95% CI 0.98–1.04; P = 0.638).
Between-hospital variation in radical treatment rates is
shown visually for each CPG using funnel plots in Fig. 2.
The observed range between the lowest and the highest
treatment rates across the 129 hospitals was largest for
CPG2 (CPG1, 0 to 72.2%; CPG2, 22.5 to 97.2%; CPG3,
33.2 to 89.3%; CPG4, 42.2 to 99.2%; CPG5, 37.3 to
97.9%). Assuming differences arise from random errors
alone, the expected number of hospitals outside the
inner (95%) funnel limits for all analyses is 6. 42 hospi-
tals (32.6%) lay outside the inner funnel limits for CPG2,
Fig. 1 Distribution of risk groups according to the five-tiered
Cambridge Prognostic Group (CPG) and the three-tiered National
Prostate Cancer Audit (NPCA)/NICE stratification system
Table 2 Patient characteristics of men diagnosed with non-metastatic prostate cancer stratified by the Cambridge Prognostic Group
(CPG)
CPG1 CPG2 CPG3 CPG4 CPG5 All men
No. % No. % No. % No. % No. % No. %
Age group (years)
< 60 2637 24.1 2627 19.3 1052 11.1 1553 12.1 1118 7.4 8987 14.5
60–69 4962 45.3 5902 43.4 3455 36.6 5142 40.1 4884 32.2 24,345 39.3
70–79 3033 27.7 4529 33.3 4276 45.2 5315 41.4 6828 45.0 23,981 38.7
≥ 80 331 3.0 530 3.9 669 7.1 821 6.4 2335 15.4 4686 7.6
Number of comorbidities (RCS Charlson score)
0 8690 79.3 10,672 78.5 7216 76.3 10,009 78.0 11,383 75.1 47,970 77.4
1 1565 14.3 1985 14.6 1531 16.2 1953 15.2 2427 16.0 9461 15.3
≥ 2 708 6.5 931 6.9 705 7.5 869 6.8 1355 8.9 4568 7.4
Deprivation status (national quintiles)
1 (least deprived) 2720 24.8 3338 24.6 2243 23.7 3048 23.8 3482 23.0 14,831 23.9
2 2620 23.9 3093 22.8 2218 23.5 3028 23.6 3613 23.8 14,572 23.5
3 2249 20.5 2847 21.0 1986 21.0 2715 21.2 3231 21.3 13,028 21.0
4 1881 17.2 2378 17.5 1647 17.4 2198 17.1 2564 16.9 10,668 17.2
5 (most deprived) 1493 13.6 1932 14.2 1358 14.4 1842 14.4 2275 15.0 8900 14.4
Ethnicity
White 9441 92.7 11,887 92.5 8198 91.6 11,268 93.0 13,437 94.0 54,231 92.9
Non-white 741 7.3 967 7.5 749 8.4 849 7.0 862 6.0 4168 7.1
Missing 781 734 505 714 866 3600
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Table 3 Radical treatment within 1 year of being diagnosed with prostate cancer according to the Cambridge Prognostic Group
(CPG)
Patients (n) Radical Tx (%) Adj. RR 95% CI P
CPG
1 10,963 1236 (11.3) 0.23 0.18–0.30 < 0.001
2 13,587 6580 (48.4) 1
3 9449 6263 (66.3) 1.44 1.36–1.53
4 12,828 10,112 (78.8) 1.69 1.32–2.15
5 15,160 11,118 (73.3) 1.70 1.37–2.11
Age group (years)
< 60 8987 5195 (57.8) 1 < 0.001
60–69 24,343 14,843 (61.0) 0.91 0.82–1.01
70–79 23,972 14,073 (58.7) 0.78 0.70–0.88
≥ 80 4685 1198 (25.6) 0.31 0.22–0.44
Number of comorbidities (RCS Charlson score)
0 47,960 27,921 (58.2) 1 0.011
1 9460 5159 (54.5) 0.95 0.73–1.24
≥ 2 4567 2229 (48.8) 0.85 0.51–1.44
Socioeconomic deprivation status (5th of national distribution)
1 (least deprived) 14,825 8525 (57.5) 1 0.267
2 14,571 8309 (57.0) 0.98 0.92–1.04
3 13,027 7428 (57.0) 0.98 0.88–1.08
4 10,666 6067 (56.9) 0.97 0.49–1.76
5 (most deprived) 8898 4980 (56.0) 0.93 0.60–1.60
Ethnicity
White 57,581 32,838 (57.0) 1 0.908
Non-white 4406 2471 (56.0) 0.98 0.87–1.13
Fig. 2 Adjusted funnel plots for the proportion of men undergoing radical treatment within 1 year of diagnosis, according to the Cambridge
Prognostic Groups at diagnosis. Each data point represents a hospital where men were diagnosed
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which was comparably higher than for the other CPGs
(CPG1, 31 hospitals (24.0%); CPG3, 33 hospitals (25.6%);
CPG4, 29 hospitals (22.4%); CPG5, 34 hospitals (26.4%)).
Treatment allocation by prognostic group
In men who received radical treatment, considerable dif-
ferences were seen in primary treatment modality ac-
cording to CPG (Table 4). The proportion of men who
received primary radiotherapy according to CPG was
similar for men in CPG3 and CPG4: 59.3% of men in
CPG3 and 59.1% in CPG4 (adjusted RR 0.99; 95% CI
0.92–1.08). More men in CPG5 however had primary
radiotherapy (79.9%) than those in CPG4 (59.1%; ad-
justed RR 1.26; 95% CI 1.12–1.40). The proportion of
men in CPG3 receiving primary radiotherapy (59.3%)
was also higher than in CPG2 (43.9%; adjusted RR 1.18;
95% CI 1.10–1.26).
In men who received radical treatment, the proportion
of men who received primary radiotherapy increased
with age (P < 0.001), the presence of comorbidities (P =
0.081), and higher levels of socioeconomic deprivation
(P < 0.003; Table 4). For example, 24.6% of men younger
than 60 years received primary radiotherapy compared
to 99.7% of men aged 80 years and above. Corresponding
percentages were 60.2% in men without comorbidities,
compared to 74% in men with two or more comorbidi-
ties, and 60.3% in men with the lowest level of socioeco-
nomic deprivation, compared to 63.7% in men with the
highest level of socioeconomic deprivation.
Discussion
This study has demonstrated that the five-tiered CPG
classification distributes men in groups that are about
equal in size. The subdivision of men with intermediate-
risk disease into CPG2 and CPG3, and of men with
high-risk disease into CGP4 and CPG5, gives a finer and
more clinically relevant degree of granularity compared
to the traditional three-tiered risk stratification system.
It is therefore more informative for studies, such as the
National Prostate Cancer Audit, that aim to evaluate the
appropriateness of treatment selection amongst pro-
viders of prostate cancer services at the regional or na-
tional level.
Table 4 Mode of treatment (surgery or radiotherapy) for those who underwent radical treatment according to the Cambridge
Prognostic Group (CPG)
Patients (n) Surgery (%) RT (%) Adj. RR 95% CI P
CPG
1 1236 726 (58.7) 510 (41.3) 0.87 0.59–1.28 < 0.001
2 6580 3691 (56.1) 2889 (43.9) 0.84 0.80–0.88
3 6263 2488 (40.7) 3775 (59 .3) 0.99 0.92–1.08
4 10,112 4133 (40.9) 5979 (59.1) 1
5 11,118 2238 (20.1) 8880 (79.9) 1.26 1.12–1.40
Age group (years)
< 60 5195 3916 (75.4) 1279 (24.6) 1 < 0.001
60–69 14,843 7275 (49.0) 7568 (51.0) 1.97 1.68–2.30
70–79 14,073 2081 (14.8) 11,992 (85.2) 3.17 2.54–3.95
≥ 80 1198 40 (0.3) 1194 (99.7) 3.52 2.84–4.37
Number of comorbidities (RCS Charlson score)
0 27,921 11,120 (39.8) 16,801 (60.2) 1 0.081
1 5159 1577 (30.6) 3582 (69.4) 1.09 1.01–1.18
≥ 2 2229 579 (26.0) 1650 (74.0) 1.12 0.99–1.27
Socioeconomic deprivation status (5th of national distribution)
1 (least deprived) 8525 3387 (39.7) 5138 (60.3) 1 0.003
2 8309 3068 (36.9) 5241 (63.1) 1.05 0.87–1.26
3 7428 2771 (37.3) 4657 (62.7) 1.07 0.77–1.50
4 6067 2244 (37.0) 3823 (63.0) 1.12 0.74–1.67
5 (most deprived) 4980 1806 (36.3) 3174 (63.7) 1.16 0.72–1.88
Ethnicity
White 32,840 12,078 (36.8) 20,760 (63.2) 1 0.922
Non-white 2469 1198 (48.5) 1273 (51.5) 0.94 0.29–3.08
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By using the CPG classification, we also demonstrated
the considerable between-hospital variation in radical
treatment rates observed for men in CPG2 across
England, which indicates a lack of consensus in the man-
agement of men with ‘favourable’ intermediate-risk dis-
ease (i.e. those in CPG2). A potential explanation for
this discrepancy may be due to the differences in the up-
take of magnetic resonance imaging techniques and
image-guided biopsies. However, we could not explore
this further due to a lack of imaging data within the data
sources that were available.
The recently updated NICE guidelines, published in
2019, currently advise active surveillance for men with
intermediate-risk disease only if they opt not to have
radical treatment. It is important to note that the NICE
guidelines do not make a distinction between favourable
(CPG2) and unfavourable (CPG3) intermediate-risk dis-
ease. Without this distinction, a clinical emphasis is
placed on treatment and not on surveillance for men in
CPG2 [1]. Equally, although the European Association of
Urology guidelines, published in 2017, make reference to
the subdivision of intermediate-risk disease into those
with favourable or unfavourable disease, the inclusion
criteria for active surveillance do not include patients
with favourable intermediate-risk disease [20].
However, other guidelines, such as those supported by
Prostate Cancer UK, do indicate that active surveillance is
suitable for men who have favourable intermediate-risk
disease and a PSA density of ≤ 0.2 ng/ml2 [21]. North
American guidelines also recommend active surveillance
as a primary management option for men with favourable
intermediate-risk disease. For example, the American Uro-
logical Association recommend offering active surveillance
to ‘select’ patients but adds the caveat that patients should
be informed that this comes with an increased risk of de-
veloping metastases without defining by how much [7].
Also, the National Comprehensive Cancer Network rec-
ommends active surveillance specifically for men with
favourable intermediate-risk disease but adds that less
than 50% of biopsy cores should be positive [8].
Using the CPG classification also sheds light on whether
men who received radical treatment had surgery or radio-
therapy. Radiotherapy appears to be a more frequent
treatment for men with more high-risk disease. Eighty per
cent of men in CPG5 underwent radiotherapy compared
to 59% in CPG4. Men in CPG5 represent those with more
locally advanced disease, for whom surgery may not be
considered appropriate. The CPG classification reveals the
differences in how men with ‘high-risk’ disease are appar-
ently selected for therapy when subdivided into CPG4 and
CPG5, which studies that used the traditional three-tiered
classification fail to demonstrate [22].
An important observation from our study is the rela-
tionship between age and CPG at diagnosis. The
proportion of men diagnosed with CPG5 aged 70 or older
was double that of those diagnosed with CPG1, indicating
a clear progression of prostate cancer stage with age and
that age at diagnosis is a major risk factor for aggressive
disease. This observation highlights the complexity of the
association of age and disease aggressiveness on the one
hand and treatment selection on the other [23, 24], given
the clinical imperative to avoid early surgical complica-
tions in older patients and to reduce the need for later sal-
vage treatments in patients with higher risk disease [25].
We also found that by using the CPG classification,
the rates of surgery exceed radiotherapy only in men
with CPG1 and CPG2 disease. Interestingly, in a prior
publication, we showed an association between being
diagnosed at a hospital with surgical services onsite
and being more likely to receive surgery for their
prostate cancer, than if these services were not avail-
able onsite [24].
A key strength of our study is that we used a contem-
porary national English cohort, ensuring that treatment
patterns were representative of the current nationwide
practice. Inclusion of more than 60,000 men who could
be classified into a CPG enabled a reliable assessment of
treatment patterns.
A major limitation of our work is that we were reli-
ant on the accuracy of the clinical coding in the rou-
tinely collected hospital data. However, the accuracy
of these data has been shown to be high when com-
pared to clinical notes and is sufficiently robust to
support its use in research [26]. It must also be noted
that the sub-classification of T stage (i.e. T2a, T2b,
and T2c) was not available. However, it is unlikely
that the use of this further sub-classification would be
beneficial given that this level of staging is known to
be frequently inaccurate [27, 28].
A further weakness is that we were unable to classify
27% into a CPG due to missing staging data. This dem-
onstrates a trade-off between a better classification sys-
tem and a higher level of data completeness when using
the five-tiered CPG instead of the three-tiered system.
Moreover, varying levels of missing data could also
introduce bias. For example, the proportion of men who
could not be classified into a CPG varied between hospi-
tals. For hospitals that were identified as outliers with
higher than expected radical treatment rates for men in
CPG2, we could not classify 21.4% into a CPG group,
whereas the corresponding figure was 18.7% for hospi-
tals identified as outliers with a lower than expected rad-
ical treatment rate.
Conclusion
In conclusion, by using the CPG classification, we could
demonstrate the potential overtreatment of favourable
intermediate-risk disease (CPG2) in England given that
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emerging evidence suggests that active surveillance is an
appropriate management strategy for this patient group.
Also, we found substantial differences in how men with
high-risk disease (CPG4 and CPG5) are managed, espe-
cially with respect to whether they get radiotherapy or
surgery. Taken together, these results strongly support
the use of a classification of prostate cancer risk that
provides a finer degree of granularity than the traditional
three-tiered classification.
Acknowledgements
We thank NHS staff for their support in collecting the clinical data, the
National Cancer Registration and Analysis Service (www.ncras.nhs.uk) for
providing Cancer Registry data and NHS Digital (www.digital.nhs.uk) for
providing Hospital Episode Statistics. MGP, TEC, AS, JN, BB, PC, NWC, HP, AA,
and JvdM are members of the Project Team of the National Prostate Cancer
Audit (www.npca.org.uk). The National Prostate Cancer Audit is
commissioned by the Healthcare Quality Improvement Partnership (HQIP) as
part of the National Clinical Audit and Patient Outcomes Programme and
funded by NHS England and the Welsh Government. Neither the funders nor
HQIP had any involvement in the study design; in the collection, analysis,
and interpretation of the data; in the writing of the report; or in the decision
to submit the article for publication.
Authors’ contributions
Designed the work: MGP, JvdM, and VG. Analysed and interpreted the data:
MGP, JvdM, and VG. Drafted the article: MGP, JvdM, and VG. Provided critical
revision: all authors. Approved final version to be published: all authors
Funding
MGP was supported by a Doctoral Research Fellowship from the NHS
National Institute for Health Research (DRF-2018-11-ST2-036). TEC was
supported by the Medical Research Council (MR/S020470/1). HP was
supported by the University College London Hospitals/University College
London Comprehensive Biomedical Research Centre. JvdM was partly
supported by the NIHR Collaboration for Leadership in Applied Health
Research and Care North Thames at Bart’s Health NHS Trust. The views
expressed in this article are those of the authors. VG acknowledges the
infrastructure support from the NHS National Institute for Health Research
Cambridge Biomedical Campus.
Availability of data and materials
The cancer registry data used for this study are based on the information
collected and quality assured by the Public Health England’s National Cancer
Registration Service (www.ncras.nhs.uk). Access to the data was facilitated by
the Public Health England’s Office for Data Release. Hospital Episode
Statistics were made available by the NHS Digital (www.digital.nhs.uk; all
rights reserved). MGP had full access to all the data in the study and takes
responsibility for the integrity of the data and accuracy of the data analysis.
Data are not available to other researchers as it uses a registry database of
patients providing routinely collected data.
Ethics approval and consent to participate
All patient data used is fully anonymised and is therefore exempt from the




JvdM reports a contract with the Healthcare Quality Improvement
Partnership (HQIP) (www.hqip.org.uk) for the provision of the National
Prostate Cancer Audit (www.npca.org.uk). HP has attended and received
honoraria for advisory boards and travel expenses to medical meetings and
served as a consultant for AstraZeneca, Astellas, Janssen, Sanofi Aventis,
Takeda, Ipsen, Ferring, Sandoz, and Novartis. NWC has attended and received
honoraria for advisory boards and travel expenses to medical meetings and
served as a consultant for AstraZeneca, Astellas, Bayer, Janssen, Sanofi
Aventis, Takeda, Ipsen, and Ferring.
Author details
1Department of Health Services Research and Policy, London School of
Hygiene and Tropical Medicine, London, UK. 2Clinical Effectiveness Unit, The
Royal College of Surgeons of England, London, England. 3Department of
Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.
4Department of Cancer Epidemiology, Population, and Global Health, King’s
College London, London, UK. 5Department of Radiotherapy, Guy’s and St
Thomas’ NHS Foundation Trust, London, UK. 6Department of Oncology,
University College London Hospitals, London, UK. 7Department of Urology,
The Christie NHS Foundation Trust, Manchester, UK. 8Department of Urology,
Salford Royal NHS Foundation Trust, Salford, UK. 9Academic Urology Group,
Department of Surgery, University of Cambridge, Cambridge, UK.
10Department of Urology, Cambridge University Hospitals NHS Foundation
Trust, Cambridge, UK. 11Cambridge Urology Translational Research and
Clinical Trials Office, Cambridge Biomedical Campus, Cambridge, UK.
Received: 28 January 2020 Accepted: 7 April 2020
References
1. National Institute for Health and Care Excellence. Prostate cancer: diagnosis
and management (2019). Available at: https://www.nice.org.uk/guidance/
ng131/resources/prostate-cancer-diagnosis-and-management-pdf-66141
714312133 (Accessed 17 July 2019).
2. Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, Pettersson A.
Predicting Prostate Cancer Death with Different Pretreatment Risk
Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort
Study. Eur Urol. 2020;77(2):180–8.
3. Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A,
Greenberg DC. Improving clinical risk stratification at diagnosis in primary
prostate cancer: a prognostic modelling study. PLoS Med. 2016;13(8):
e1002063.
4. Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, et al. The
Cambridge Prognostic Groups for improved prediction of disease mortality
at diagnosis in primary non-metastatic prostate cancer: a validation study.
BMC Med. 2018;16(1):31.
5. Gnanapragasam VJ, Barrett T, Thankapannair V, Thurtle D, Rubio-Briones J,
Dominguez-Escrig J, et al. Using prognosis to guide inclusion criteria, define
standardised endpoints and stratify follow-up in active surveillance for
prostate cancer. BJU Int. 2019;124(5):758–67.
6. Egevad L, Delahunt B, Srigley JR, Samaratunga H. International Society of
Urological Pathology (ISUP) grading of prostate cancer - an ISUP consensus
on contemporary grading. Apmis. 2016;124(6):433–5.
7. American Urological Association. Clinically localized prostate cancer (2017).
Available at: http://www.auanet.org/guidelines/clinically-localized-prostate-
cancer-new-(aua/astro/suo-guideline-2017)#x6912 (Accessed 17 July 2019).
8. National Comprehensive Cancer Network. NCCN Guidelines (2016). Available
at: https://www.nccn.org/about/news/ebulletin/ebulletindetail.
aspx?ebulletinid=666 (Accessed 17 July 2019).
9. National Prostate Cancer Audit. Annual Report 2018: Results of the NPCA
Prospective Audit in England and Wales for men diagnosed from 1 April
2016 - 31 March 2017. Available at: https://www.npca.org.uk/reports/npca-
annual-report-2018/ (Accessed 14 May 2019).
10. World Health Organisation. International Statistical Classification of Diseases
and Related Health Problems (10th Revision). Available at: http://www.who.
int/classifications/icd/ICD10Volume2_en_2010.pdf (Accessed 28 Sept 2017).
11. National Cancer Intelligence Network. National Cancer Data Repository.
Available at: http://www.ncin.org.uk/collecting_and_using_data/national_
cancer_data_repository/ (Accessed 11 Dec 2016).
12. National Health Service. Hospital Episode Statistics Available at: http://www.
hesonline.nhs.uk (Accessed 15 Jan 2017).
13. National Cancer Registration and Analysis Service. National Radiotherapy
Dataset (RTDS) Available at: http://www.ncin.org.uk/collecting_and_using_
data/rtds (Accessed 11 Dec 2017).
14. Parry MG, Sujenthiran A, Cowling TE, Charman S, Nossiter J, Aggarwal A,
et al. Imputation of missing prostate cancer stage in English cancer registry
data based on clinical assumptions. Cancer Epidemiol. 2019;58:44–51.
15. Noble M, McLennan D, Wilkinson K, Whitworth A, Dibben C, Barnes H. The
English Indices of Deprivation 2007. Available at: http://geoconvert.mimas.
ac.uk/help/imd-2007-manual.pdf (Accessed 28 Sept 2017).
Parry et al. BMC Medicine          (2020) 18:114 Page 8 of 9
16. Armitage JN, van der Meulen JH, Royal College of Surgeons Co-morbidity
Consensus G. Identifying co-morbidity in surgical patients using
administrative data with the Royal College of Surgeons Charlson Score. Br J
Surg. 2010;97(5):772–81.
17. NHS Digital. NHS Classifications Service: OPCS classifications of interventions
and procedures version 4.4; Available at: http://systems.digital.nhs.uk/data/
clinicalcoding/codingstandards/opcs4 (Accessed 28 Sept 2017).
18. Knol MJ, Le Cessie S, Algra A, Vandenbroucke JP, Groenwold RH.
Overestimation of risk ratios by odds ratios in trials and cohort studies:
alternatives to logistic regression. CMAJ. 2012;184(8):895–9.
19. Spiegelhalter DJ. Funnel plots for comparing institutional performance. Stat
Med. 2005;24(8):1185–202.
20. European Association of Urology. Guidelines on prostate cancer (2017)
Available at: http://uroweb.org/guideline/prostate-cancer/
(Accessed 16 Feb 2018).
21. Prostate Cancer UK. Brest practice in active surveillance for prostate cancer:
a consensus guideline for health professionals (2019). Available at: https://
prostatecanceruk.org/media/2498337/5682-plain-english-consensus-
guideline-final.pdf (Accessed 7 Aug 2019).
22. Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, et al.
Comparative effectiveness of radical prostatectomy and radiotherapy in
prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:
g1502.
23. Lunardi P, Ploussard G, Grosclaude P, Roumiguie M, Soulie M, Beauval JB,
et al. Current impact of age and comorbidity assessment on prostate cancer
treatment choice and over/undertreatment risk. World J Urol. 2017;35(4):
587–93.
24. Parry MG, Sujenthiran A, Cowling TE, Nossiter J, Cathcart P, Clarke NW, et al.
Impact of cancer service centralisation on the radical treatment of men
with high-risk and locally advanced prostate cancer: a national cross-
sectional analysis in England. Int J Cancer. 2019;145(1):40–8.
25. Payne HA, Gillatt DA. Differences and commonalities in the management of
locally advanced prostate cancer: results from a survey of oncologists and
urologists in the UK. BJU Int. 2007;99(3):545–53.
26. Burns EM, Rigby E, Mamidanna R, Bottle A, Aylin P, Ziprin P, et al. Systematic
review of discharge coding accuracy. J Public Health (Oxf). 2012;34(1):138–48.
27. Reese AC, Cooperberg MR, Carroll PR. Minimal impact of clinical stage on
prostate cancer prognosis among contemporary patients with clinically
localized disease. J Urol. 2010;184(1):114–9.
28. Reese AC, Sadetsky N, Carroll PR, Cooperberg MR. Inaccuracies in
assignment of clinical stage for localized prostate cancer. Cancer. 2011;
117(2):283–9.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Parry et al. BMC Medicine          (2020) 18:114 Page 9 of 9
